AMT-240 / uniQure - LARVOL DELTA

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs (GlobeNewswire) - "Prioritizing continued development of AMT-130 in Huntington’s disease and near-term...uniQure N.V...today announced a strategic reorganization that will significantly reduce operating expenses while supporting focused execution to rapidly advance multiple clinical-stage programs to proof-of-concept....The company will focus its research efforts on a limited number of projects believed to have optimal risk, value and speed attributes, including AMT-161 for c9orf72 amyotrophic lateral sclerosis (ALS), AMT-240 for autosomal dominant Alzheimer's disease, and next-generation AAV capsid development. As a result of the reprioritization, the Company will be closing a research lab in Lexington and plans to sublease this space."

Pipeline update • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Huntington's Disease

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "...the Company hosted a virtual Research & Development Day to highlight new investments in its expanding gene therapy pipeline focusing on central nervous system and rare, liver-directed disorders, as well as new advancements in platform technology and manufacturing. Three new, internally developed pre-clinical programs were announced in Parkinson’s disease (AMT-210), Parkinson’s disease (AMT-210), amyotrophic lateral sclerosis (ALS) (AMT-161), and autosomal dominant Alzheimer’s disease (AMT-240)."

Preclinical • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease